

NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE
COMPOUNDS

Abstract of the Disclosure

5

Novel diphenylethylene compounds and derivatives thereof
containing thiazolidinedione or oxazolidinedione moieties are provided which
are effective in lowering blood glucose level, serum insulin, triglyceride and
free fatty acid levels in animal models of Type II diabetes. In contrast to
10 previously reported thiazolidinedione compounds, known to lower leptin
levels, the present compounds increase leptin levels and have no known liver
toxicity. The compounds are disclosed as useful for a variety of treatments
including the treatment of inflammation, inflammatory and immunological
diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer
15 and multiple sclerosis.